The study follows a structured sequence typical of biopharmaceutical development:
The next step in the bioprocess development of A Mab was the development of a scalable fermentation process. A Mab was produced in a fed-batch mode using a 50 L bioreactor. The fermentation process involved a combination of batch and fed-batch phases, with a cell growth phase followed by a production phase.
Programmed automated feeding to maintain glucose levels between 2.0 and 4.0 g/L, preventing osmotic shock and minimizing toxic byproduct accumulation.
The case study concludes with a summary of key performance indicators (KPIs) for Mab-X:
Process characterization involves understanding how various parameters affect these quality attributes. This is often done using a approach to efficiently study multiple variables at once. A Mab A Case Study In Bioprocess Development
: It uses tools like Failure Mode and Effect Analysis (FMEA) to assess how process parameters impact product quality.
A-Mab: A Case Study in Bioprocess Development Published in 2009 by a collaboration of major biopharmaceutical companies, it provides a comprehensive framework for navigating product characterization, upstream cell cultivation, downstream purification, and risk-based regulatory filings. Rather than treating biological manufacturing as a rigid protocol, the A-Mab model illustrates how advanced process knowledge allows manufacturers to establish flexible operating bounds called a design space. 1. Foundations of the A-Mab Framework
This public link is valid for 7 days and shares a thread, including any personal information you added. This link or copies made by others cannot be deleted. If you share with third parties, their policies apply. Can’t copy the link right now. Try again later.
The goal of upstream development is to create a robust cell culture process that maximizes yield (titer) while maintaining CQAs. The study follows a structured sequence typical of
One critical insight: Routine HCP ELISA does not detect a specific CHO protein (Cathepsin D) that co-elutes with Mab-X during AEX. The team adds a secondary orthogonal method (LC-MS/MS) to verify HCP clearance.
The purification process was scaled up from a 10 mL to a 100 L scale, demonstrating excellent scalability.
The , published by the CMC Biotech Working Group , is a foundational document in the biopharmaceutical industry. It serves as a mock regulatory submission to demonstrate how Quality by Design (QbD) principles from ICH guidelines (Q8, Q9, and Q10) can be applied to the development of a monoclonal antibody . 1. Identify Quality Attributes
Having developed a robust process at 50 L and 200 L pilot scales, the team transfers to a 10,000 L commercial facility. The case study highlights three common pitfalls: : It uses tools like Failure Mode and
Bioprocess scale-up is a delicate balancing act. While small-scale models are essential for development, they cannot fully replicate the complexities of large-scale production. For instance, a standard procedure for cell culture supernatant (CCS) is common in process development, but it is often avoided in manufacturing to prevent product degradation. A case study in Biotechnology and Bioengineering revealed that when CCS is frozen, large particles based on mAbs and specific HCPs can form, affecting purification. It was concluded that CCS should be frozen as rapidly as possible during process development to minimize these issues and ensure data transferability to manufacturing.
: While accelerated timelines are possible (e.g., 4 months for process characterization), they require a robust, risk-based focus on the control strategy.
An overview of methods used in bioreactor optimization.
High turbidity in the load causes column fouling and pressure spikes >3 bar.